Search

Search results

194 results found

Lower drug clearance of adalimumab is associated with proactive therapeutic drug monitoring and mucosal healing in patients with inflammatory bowel disease.

Deyhim, Tina, Alessandra Saraga, Ajay Gade, Grace Geeganage, Mostafa A Soliman, Samantha Zullow, Loren G Rabinowitz, et al. 2026. “Lower Drug Clearance of Adalimumab Is Associated With Proactive Therapeutic Drug Monitoring and Mucosal Healing in Patients With Inflammatory Bowel Disease.”. European Journal of Gastroenterology & Hepatology.

Retraction notice to "Screening for novel central nervous system biomarkers in veterans with Gulf War Illness" [Neurotoxicology and Teratology 61 (2017) 36-46].

Abou-Donia, Mohamed B, Lisa A Conboy, Efi Kokkotou, Eric Jacobson, Eman M Elmasry, Passent Elkafrawy, Megan Neely, Cameron R Dale Bass, and Kimberly Sullivan. 2025. “Retraction Notice to ‘Screening for Novel Central Nervous System Biomarkers in Veterans With Gulf War Illness’ [Neurotoxicology and Teratology 61 (2017) 36-46].”. Neurotoxicology and Teratology 107: 107423.

Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab.

Porth, Rachel, Tina Deyhim, Samantha Zullow, Loren G Rabinowitz, Laurie B Grossberg, Xavier Roblin, Stephane Paul, Adam S Cheifetz, and Konstantinos Papamichael. 2025. “Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab.”. Inflammatory Bowel Diseases 31 (2): 485-91.